1.
Bioorg Med Chem Lett
; 28(8): 1392-1396, 2018 05 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-29548573
RESUMEN
A second-generation small molecule P2X3 receptor antagonist has been developed. The lead optimization strategy to address shortcomings of the first-generation preclinical lead compound is described herein. These studies were directed towards the identification and amelioration of preclinical hepatobiliary findings, reducing potential for drug-drug interactions, and decreasing the projected human dose of the first-generation lead.